Blog

7 March 2016 - The reincarnation of the Cancer Drugs Fund will benefit both NICE and the NHS. ...

8 March 2016 - Cost regulators for the NHS in England and Wales are leaning towards a ‘no’ on the use ...

7 March 2016 - The SMC has rejected Opdivo as a monotherapy for the treatment of advanced melanoma, and Perjeta for ...

7 March 2016 - The Scottish Medicines Consortium has today published advice accepting three new medicines for routine use in NHS ...

7 March 2016 - Pharmac's assignment of a low-funding priority to pembrolizumab (Keytruda) for advanced melanoma has brought cancer drug funding ...

6 March 2016 - If my child was dying of a disease and there was a drug that could help her ...

6 March 2016 - The melanoma drug Keytruda should be funded here, Labour says -- despite the head of PHARMAC saying ...

4 March 2016 - The public summary documents (recommendations and subsequent decisions not to recommend) from the November 2015 PBAC meeting ...

4 March 2016 - The public release documents from the utilisation analyses considered at the October 2015 DUSC meeting are now ...

4 March 2016 - The public submission process is now open for the Post-market Reviews of ezetimibe and medicines for COPD. The ...

3 March 2016 - Is Pharmac’s decision not to prioritise funding melanoma drug Keytruda a case of “putting money before people”, ...

3 March 2016 - The NZ Government has all but promised that a melanoma drug will be funded by Pharmac after ...

2 March 2016 - Consider this, you're a multinational company peddling a relatively new melanoma cancer drug that's been effective for ...

1 March 2016 - A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's ...